Literature DB >> 18452152

Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells.

Zheng Meng1, Nateka L Jackson, Hyoungsoo Choi, Peter H King, Peter D Emanuel, Scott W Blume.   

Abstract

The type I insulin-like growth factor receptor (IGF-IR) is integrally involved in the control of cellular proliferation and survival. An internal ribosomal entry site (IRES) within the 1,038 nucleotide 5'-untranslated region of the human IGF-IR mRNA helps to provide the tight control of IGF-IR expression necessary for maintenance of normal cellular and tissue homeostasis. The IRES maps to a discrete sequence of 85 nucleotides positioned just upstream of the IGF-IR initiation codon, allowing the ribosome to bypass the highly structured regions of the 5'-UTR as well as the upstream open reading frame. The authenticity of the IGF-IR IRES has been confirmed by its sensitivity to deletion of the promoter from a bicistronic reporter construct, and its resistance in a monocistronic reporter construct to co-expression of a viral 2A protease. We previously characterized HuR as a potent repressor of IGF-IR translation. Here we demonstrate that hnRNP C competes with HuR for binding the IGF-IR 5'-UTR and enhances IRES-mediated translation initiation in a concentration-dependent manner. We observed changes in binding of hnRNP C versus HuR to the IGF-IR 5'-UTR in response to physiological alterations in cellular environment or proliferative status. Furthermore, we have found distinct alterations in the pattern of protein binding to the IGF-IR 5'-UTR in human breast tumor cells in which IGF-IR IRES activity and relative translational efficiency are aberrantly increased. These results suggest that dysregulation of the IGF-IR IRES through changes in the activities of RNA-binding translation-regulatory proteins could be responsible for IGF-IR overexpression in a proportion of human breast tumors. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452152     DOI: 10.1002/jcp.21486

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  34 in total

1.  Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.

Authors:  Scott W Blume; Nateka L Jackson; Andra R Frost; William E Grizzle; Oleg D Shcherbakov; Hyoungsoo Choi; Zheng Meng
Journal:  Exp Mol Pathol       Date:  2010-03-15       Impact factor: 3.362

Review 2.  Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states.

Authors:  Anton A Komar; Maria Hatzoglou
Journal:  Cell Cycle       Date:  2011-01-15       Impact factor: 4.534

3.  The human IGF1R IRES likely operates through a Shine-Dalgarno-like interaction with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by a naturally polymorphic polyU loop.

Authors:  Zheng Meng; Nateka L Jackson; Oleg D Shcherbakov; Hyoungsoo Choi; Scott W Blume
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

4.  Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage.

Authors:  Marie-Jo Halaby; Benjamin R E Harris; W Keith Miskimins; Margot P Cleary; Da-Qing Yang
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

Review 5.  Biomarkers and the genetics of early neoplastic lesions.

Authors:  Sudhir Srivastava; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

6.  Hu antigen R (HuR) is a positive regulator of the RNA-binding proteins TDP-43 and FUS/TLS: implications for amyotrophic lateral sclerosis.

Authors:  Liang Lu; Lei Zheng; Ying Si; Wenyi Luo; Gwendal Dujardin; Thaddaeus Kwan; Nicholas R Potochick; Sunnie R Thompson; David A Schneider; Peter H King
Journal:  J Biol Chem       Date:  2014-09-19       Impact factor: 5.157

7.  Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.

Authors:  Esther A Suswam; John J Shacka; Kiera Walker; Liang Lu; Xuelin Li; Ying Si; Xiaowen Zhang; Lei Zheng; L Burt Nabors; Heping Cao; Peter H King
Journal:  J Neurooncol       Date:  2013-03-25       Impact factor: 4.130

8.  IGF-IR and its inhibitors in gastrointestinal carcinomas (Review).

Authors:  Xiao Hong Bao; Yoshio Naomoto; Hui Fang Hao; Nobuyuki Watanabe; Kazufumi Sakurama; Kazuhiro Noma; Takayuki Motoki; Yasuko Tomono; Takuya Fukazawa; Yasuhiro Shirakawa; Tomoki Yamatsuji; Junji Matsuoka; Munenori Takaoka
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

9.  Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.

Authors:  Po-Chen Chu; Samuel K Kulp; Ching-Shih Chen
Journal:  Carcinogenesis       Date:  2013-07-16       Impact factor: 4.944

10.  The human insulin receptor mRNA contains a functional internal ribosome entry segment.

Authors:  Keith A Spriggs; Laura C Cobbold; Simon H Ridley; Mark Coldwell; Andrew Bottley; Martin Bushell; Anne E Willis; Kenneth Siddle
Journal:  Nucleic Acids Res       Date:  2009-08-04       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.